Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23771120 | 0.84 | SMN1; SMN2 (0.47) | ALDH1A1CYP2C19RAB9AHTTNPC1 | |
| SCHEMBL26617759 | 0.81 | ERN1 (0.42) | ALDH1A1CYP2C19RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL16800087 | 0.80 | ERN1 (0.52) | ALDH1A1EGFRERN1MAPTPOLB | |
| SCHEMBL15428158 | 0.80 | L3MBTL1 (0.43) | ALDH1A1CYP2C19RAB9AHTTNPC1 | |
| SCHEMBL4047337 | 0.80 | MEN1 (0.45) | ALDH1A1RAB9AHTTNPC1MAPT | |
| SCHEMBL1721489 | 0.79 | HTT (0.64) | ALDH1A1CYP2C19RAB9AHTTNPC1 | |
| SCHEMBL28298268 | 0.77 | ALDH1A1 (0.42) | ALDH1A1CYP2C19HTTHDAC1ERN1 | |
| SCHEMBL17980719 | 0.76 | ERN1 (0.56) | ALDH1A1RAB9ANPC1SMN1; SMN2ERN1 | |
| SCHEMBL38663965 | 0.76 | RAB9A (0.73) | ALDH1A1RAB9AHTTNPC1SMN1; SMN2 | |
| SCHEMBL29954656 | 0.76 | KCNQ4 (0.46) | HTTPOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3310777-B1 | DIAMIDE MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-09 | — | — | EP | disclosed |
| US-10160750-B2 | Diamide macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-12-25 | — | — | US | disclosed |
| US-20180141932-A1 | DIAMIDE MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141932-A1 | DIAMIDE MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | ALDH1A1 4091/4885CYP2C19 785/4885RAB9A 2857/4885 |
| US-10160750-B2 | Diamide macrocycles as factor XIa inhibitors | TFPI, TFPI2, F11 | ALDH1A1 4091/4885CYP2C19 785/4885RAB9A 2857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.